David Rial-Crestelo

6PUBLICATIONS
30CO-AUTHORS
Applied linguistics and educational linguisticsMedical molecular engineering of nucleic acids and proteinsPredictive and prognostic markersGene and molecular therapyMedical virology
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (6)

|Aug 21, 2026
Effectiveness of dolutegravir/lamivudine versus bictegravir/emtricitabine/tenofovir alafenamide in people with HIV with very high viral load (≥500 000 copies/mL).

|Jul 16, 2026
Effect of Non-nucleoside Resistance-Associated Mutations on the Effectiveness of Long-Acting Cabotegravir + Rilpivirine Therapy: Insights From the Real-World RELATIVITY Cohort.

|Jun 27, 2025
Longitudinal Immunoprofiling of the CD8+ T-Cell Response in SARS-CoV-2 mRNA Vaccinees and COVID-19 Patients.

Jesús Emanuel Brunetti, Beatriz Escudero-Pérez, Fátima Lasala

|Nov 30, 2023
Virologic Response to Dolutegravir Plus Lamivudine in People With Suppressed Human Immunodeficiency Virus Type 1 and Historical M184V/I: A Systematic Literature Review and Meta-analysis.

Madhusudan Kabra, Tristan J Barber, Clotilde Allavena

|Apr 26, 2023
Effectiveness and tolerability of dolutegravir/lamivudine for the treatment of HIV-1 infection in clinical practice.

Inés Suárez-García, Belén Alejos, Victoria Hernando

|Nov 30, 2022
Long-term Evaluation of Residual Viremia in a Clinical Trial of Dolutegravir Plus Lamivudine as Maintenance Treatment for Participants With and Without Prior Lamivudine Resistance.

Rosa De Miguel Buckley, David Rial-Crestelo, Rocío Montejano

Pageof 1

Frequent Collaborators

2 joint publications

Rafael Delgado

2 joint publications

Federico Pulido

1 joint publications

Rosa De Miguel Buckley

1 joint publications

Inés Suárez-García